LD-2 disclosure · 4th Quarter - Report
SAGHMOS THERAPEUTICS, INC.
Client
- Name
- SAGHMOS THERAPEUTICS, INC.
- Description
- Bio-pharmaceutical company
- Location
- Connecticut · United States of America
Registrant
- Description
- public policy consulting
- Location
- Arlington, Virginia, United States of America
Lobbying activities
2 issuesHealth Issues
Policies to address health disparities in kidney disease, patient literacy, diversity in clinical trial participation, FDA/CMS communications, and Medicare payment modernization, generally, and related to H.R. 6000, Cures 2.0 Act. Education and awareness, regarding treatment of contrast-induced acute kidney injury after percutaneous coronary intervention.
LobbyistsJENNIFER BELL · MELISSA BARTLETT · mr ARIEL ALEJANDRO GONZALEZ esq
Covered position (JENNIFER BELL): Health Policy Advisor, Sen. Finance Committee
Covered position (MELISSA BARTLETT): Counsel, U.S. House of Representatives, Committee on Energy and Commerce
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
Medicare beneficiary access to a potential treatment to prevent contrast-induced acute kidney injury and major adverse renal and cardiac events after percutaneous coronary intervention, as well as potential savings to Medicare and beneficiaries to such prevention.
LobbyistsJENNIFER BELL · MELISSA BARTLETT · mr ARIEL ALEJANDRO GONZALEZ esq
Covered position (JENNIFER BELL): Health Policy Advisor, Sen. Finance Committee
Covered position (MELISSA BARTLETT): Counsel, U.S. House of Representatives, Committee on Energy and Commerce
SENATE · HOUSE OF REPRESENTATIVES